Clene Inc (CLNNW) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Clene Inc (CLNNW) has a cash flow conversion efficiency ratio of 0.322x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.98 Million) by net assets ($-12.36 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CLNNW net asset quality index to measure how much of total assets are equity-financed.
Clene Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Clene Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Clene Inc (CLNNW) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Clene Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Clene Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ordinary Fully Paid Deferred Settlement
AU:1TTDB
|
-0.108x |
|
Liberty Metals Ltd
AU:LIB
|
N/A |
|
Arko Corp
NASDAQ:ARKOW
|
0.132x |
|
Kardan NV
TA:KRNV
|
-0.001x |
|
Hall of Fame Village LLC
NASDAQ:HOFVW
|
-0.053x |
|
Jasmine International Public Company Limited
F:JASN
|
0.020x |
|
Lexaria Bioscience Corp
NASDAQ:LEXXW
|
-0.218x |
|
Aquis Exchange PLC
LSE:AQX
|
0.057x |
Annual Cash Flow Conversion Efficiency for Clene Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Clene Inc from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see Clene Inc (CLNNW) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-8.86 Million | $-21.33 Million | 2.408x | +206.86% |
| 2023-12-31 | $13.39 Million | $-30.17 Million | -2.253x | +81.30% |
| 2022-12-31 | $3.24 Million | $-39.01 Million | -12.052x | -338.46% |
| 2021-12-31 | $12.60 Million | $-34.62 Million | -2.749x | +95.05% |
| 2020-12-31 | $341.00K | $-18.93 Million | -55.510x | -1955.61% |
| 2019-12-31 | $4.89 Million | $-13.20 Million | -2.700x | -6474.48% |
| 2018-12-31 | $5.00 Million | $-205.37K | -0.041x | -104.11% |
| 2017-12-31 | $-2.39K | $-2.39K | 1.000x | -- |
About Clene Inc
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis … Read more